insilico medicine investor presentation
Busts 3 Costly Longevity Science Investment Myths
The three most costly myths in longevity science investing are the belief that telomere lengthening alone drives returns, that DIY biohacking can scale into pharma, and that genetic longevity guarantees quick exits. In the three global summits where Insilico Medicine presented in early October, more than 120 fund managers asked